Musso Alan A 4

What Happened

• Alan A. Musso, Chief Financial Officer of Fulcrum Therapeutics (FULC), received a grant of 170,000 derivative shares (an option award) on February 2, 2026. The filing reports an acquisition amount of 170,000 shares at $0.00 (derivative instrument); no cash was exchanged in the filing.

Key Details

• Transaction date: 2026-02-02; SEC filing date: 2026-02-04 (timely filing).
• Instrument: Option award covering 170,000 shares (reported as a derivative acquisition).
• Reported price/value: $0.00 in the Form 4 entry (no cash paid shown).
• Vesting: Scheduled to vest in equal quarterly installments over four years, beginning with a vesting commencement date of January 1, 2026, subject to continued service (per footnote).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.

Context

• This is an equity incentive (option) grant, a common form of executive compensation intended for retention and alignment with shareholder interests. It does not represent an immediate open‑market purchase or sale of stock, nor an immediate realized cash value unless/when options are exercised and shares sold.